Postmenopausal OsteoporosisSymptoms, Doctors, Treatments, Advances & More
Learn About Postmenopausal Osteoporosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
CUIMC/Harkness Pavilion
Ethel Siris is an Internal Medicine provider in New York, New York. Dr. Siris is rated as an Elite provider by MediFind in the treatment of Postmenopausal Osteoporosis. Her top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Paget's Disease of Bone, Melorheostosis, and Hormone Replacement Therapy (HRT).
University Of Pittsburgh Physicians, Department Of Medicine, Geriatric Medicine
Susan Greenspan, MD, is an internationally respected osteoporosis researcher whose specialties are the effects of osteoporosis in elderly women, and the assessment of new techniques to examine bone density and rate of bone loss and therapies to maintain bone health. Dr. Greenspan is very interested in educating the community and other physicians about osteoporosis. Dr. Greenspan is rated as an Elite provider by MediFind in the treatment of Postmenopausal Osteoporosis. Her top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Infertility, Hypogonadism Primary Partial Alopecia, and Hormone Replacement Therapy (HRT).
NewYork Presbyterian Columbia University Irving Medical Center
John Bilezikian is an Internal Medicine provider in New York, New York. Dr. Bilezikian is rated as an Elite provider by MediFind in the treatment of Postmenopausal Osteoporosis. His top areas of expertise are Hyperparathyroidism, Hypoparathyroidism, Hypercalcemia, Parathyroidectomy, and Hormone Replacement Therapy (HRT).
Summary: Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to prevent or attenuate this highly vulnerable period of bone loss which, if successfully attenuated, can potentially prevent/delay osteoporosis in women. The transmenopausal period represents an opportunistic window for the study because bone...
Summary: Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of bi...